Text Size

Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2003 by National Center for Research Resources (NCRR).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Children's Hospital Medical Center, Cincinnati
Information provided by:
National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:
NCT00005105
First received: April 6, 2000
Last updated: June 23, 2005
Last verified: December 2003
History of Changes
  Purpose

OBJECTIVES:

I. Determine if mutations in the gene encoding the insulin-like growth factor-I receptor lead to relative insulin-like growth factor-I insensitivity and produce intrauterine growth retardation in children.


Condition
Intrauterine Growth Retardation

Study Type: Observational
Study Design: Primary Purpose: Screening

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Center for Research Resources (NCRR):

Estimated Enrollment: 75
Study Start Date: January 1997
Detailed Description:

PROTOCOL OUTLINE:

Patients undergo blood draw. Insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) are measured. Patients whose IGF-I and IGFBP-3 levels are average or above are tested for the presence of mutation in the insulin-like growth factor-I receptor.

  Eligibility

Ages Eligible for Study:   18 Months to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Intrauterine growth retardation (IUGR), defined as birth weight less than 2 standard deviations below the mean by Usher and McLean Deficient "catch-up" growth (stature less than 5th percentile on growth chart after age 18 months) Normal or elevated circulating concentrations of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) IGF-I or IGFBP-3 within or above the 95th percentile confidence interval for age No other clinical explanation for poor prenatal and postnatal growth No IUGR due to maternal toxemia, endocrine disease, gastrointestinal disease, significant heart disease, or chromosomal abnormalities No other condition known to retard growth
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005105

Locations
United States, Georgia
Emory University School of Medicine Terminated
Atlanta, Georgia, United States, 30322
United States, Indiana
James Whitcomb Riley Hospital for Children Active, not recruiting
Indianapolis, Indiana, United States, 46202-5225
United States, New York
Schneider Children's Hospital Recruiting
New Hyde Park, New York, United States, 11042
Contact: Graeme Frank     718-470-3390        
United States, Ohio
Children's Hospital Medical Center - Cincinnati Recruiting
Cincinnati, Ohio, United States, 45229-3039
Contact: Steven D. Chernausek     513-636-4744        
United States, Virginia
Medical College of Virginia School of Medicine Recruiting
Richmond, Virginia, United States, 23298-0230
Contact: Paul Kaplowitz     804-786-9788        
Sponsors and Collaborators
National Center for Research Resources (NCRR)
Children's Hospital Medical Center, Cincinnati
Investigators
Study Chair: Steven D. Chernausek Children's Hospital Medical Center, Cincinnati
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00005105     History of Changes
Other Study ID Numbers: 199/14924, CHMC-C-96-10-4
Study First Received: April 6, 2000
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):
endocrine disorders
intrauterine growth retardation
rare disease

Additional relevant MeSH terms:
Fetal Growth Retardation
Fetal Diseases
Pregnancy Complications
Growth Disorders
Pathologic Processes

ClinicalTrials.gov processed this record on May 23, 2013